CTOs on the Move


 
Indiva is a Canadian licensed producer of premium cannabis and cannabis products, and a provider of extraction, manufacturing and refinement services.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.indiva.com
  • 1050 Hargrieve Drive Unit 10
    London, ON CAN N6E 1P5
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Indiva raised $14M on 10/16/2019
Indiva raised $11M on 02/16/2021

Similar Companies

Mccrone Group Inc

Mccrone Group Inc is a Westmont, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.

Zavante Therapeutics

Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.

Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.

Novartis Vaccines and Diagnostics,Inc.

Novartis Vaccines and Diagnostics,Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.